At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 26 enrolled
Drug / intervention
Pentoxifylline +1 moredrug
Likely dose
Pentoxifylline 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Pentoxifylline on Nonalcoholic Steatohepatitis (NASH)
In Brief
A Phase 3 clinical trial evaluating Pentoxifylline and Placebo for Nonalcoholic Steatohepatitis and Liver Diseases. Completed, enrolled 26 participants across 1 site.
Detailed Summary
The purpose of this study is to explore the potential benefit of the medication, pentoxifylline, for the treatment of NASH.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNonalcoholic Steatohepatitis, Liver Diseases
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2005
First PostedDec 2005
Primary CompletionSep 2009
TodayJul 2026
First PostedDec 21, 2005
Enrollment StartMar 1, 2005
Primary CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 20.5 years ago
Interventions
Pentoxifyllinedrug
400mg PO TID
Placebodrug
1 pill PO TID